.
Human breast cancer is a malignant disease with an often unpredictable clinical course. Those clinico-pathological tumour characteristics in current use do not always give sufficient information for the prediction of the individual tumour behaviour. In the attempt to find additional 'markers' which are associated with potential tumour aggression and in order to get a better understanding of the tumour biology, numerous antibodies have been raised against various antigens of human malignant tumours or their cell lines (Rittenhouse et al., 1985) . Though antibodies raised against glycoproteins and proteins often are not organ specific and interestingly also immunoreact with non-neoplastic and or foetal tissue, close associations between the immunohistochemical expression of such glycoproteins and malignant tumours have been reported (Rittenhouse et al., 1985) .
In this context, the murine IgM monoclonal antibody A-80 has been raised against a purified high molecular weight mucin-type glycoprotein derived from the human colon adenocarcinoma cell line LS-147T Jansson et al., 1988) . antigen comprises heterogeneous glycoproteins with Mr ranging from 25 to greater than 200 kDa. The antigenic epitope consists of both oligosaccharides and polypeptides and N-acetylgalactosamine is an integral part (Kim et al., 1991) . The antibody has been shown to immunostain neoplastic cells of carcinomas of the colon, pancreas, prostate, lung, and breast (Jansson et al., 1988) . In breast disease, various degrees of immunohistochemical expression of the A-80 antigen were not only found in the vast majority of the malignant lesions, but also observed in benign proliferative breast disease, especially in epithelial hyperplasias with atypia (Jansson et al., 1988; Eriksson et al., 1992 (Rutqvist et al., 1989) . Patients were followed up for disease recurrence and survival status as described elsewhere (Schimmelpenning et al., 1990 (Kim et al., 1991) , at a dilution of 1:230 in TBS, containing 1% bovine serum albumin and 0.015% sodium azide, at 8'C overnight. Diaminobenzidine was used as chromogen. Finally, the specimens were counterstained with Mayer's hematoxylin. Negative controls were sections of a known immunoreactive case incubated with inactivated mouse serum instead of the primary antibody.
Tissue sections were classified as immunoreactive when a distinct cytoplasmic staining pattern was observed. In contrast, a positive immunoreaction on intraluminal secretion without co-existing cytoplasmic staining pattern was considered nonspecific. Immunohistochemical staining results were evaluated as described previously (Eriksson et al., 1992) . The staining intensity was evaluated, and at the same time, a semi-quantitative assessment was carried out by estimating the percentage of immunoreactive cells (Koukoulis et al., 1990) . Samples were graded from negative (-) to 3 + positive: (-= less than 5%, 1 + = 5-20%, 2 + = 21-50%, 3 + = more than 50%).
Cytometrical DNA assessments and histogram evaluation The nuclear DNA content was assessed by means of image cytometry according the Feulgen technique as described previously (Fallenius et al., 1986) . The detailed DNA assessment technique, including staining, internal standardisation, and tumour cell selection was reported elsewhere (Fallenius et al., 1988) . The cytometrical DNA histograms were classified into four different types according to criteria described by Auer et al. (1980) (Cutler & Ederer, 1958) . Deaths that were not preceded by distant metastases were censored at the time of death in the survival analysis. Univariate and multivariate analyses were performed using Cox's proportional hazards regression model (Cox, 1972 (Armitage, 1971a,b la-c) .
In univariate analysis, the associations of the above mentioned tumour characteristics to distant metastases-free survival were investigated. The degree of immunohistochemical A-80 expression was found to be of significant prognostic value (P = 0.03) (Figure 2 ). (Table II) .
Of the other tumour characteristics included in the univariate analysis, nodal status, tumour size, and nuclear DNA histogram type were also of significant prognostic value (Table III) . The histopathological tumour grade, treatment and menopausal status were not related to the distant Table III . The prognostic significance of MAb A-80 immunostaining was reduced but retained borderline significance (P = 0.08). Nodal status, tumour size, and nuclear DNA histogram type were found to provide significant independent prognostic information. Immunohistochemical expression of the A-80 antigen has been observed in the vast majority of invasive mammary carcinomas in an elaborate study by Koukoulis et al. (1990) . In the same study, most of the investigated benign mammary lesions did not immunoreact with the MAb A-80. We conducted a study comprising 204 invasive breast carcinomas and found MAb A-80 immunostaining in 88% of the tumours (Eriksson et al., 1992) . However, the number of the immunoreactive tumour cells and the intensity of immunostaining varied between tumour specimens. While in some invasive tumours only about 5% of the neoplastic cells immunostained, other malignant variants had more than 50% immunoreactive cells. This observation was shared by others (Koukoulis et al., 1990; Shin et al., 1989) . Interestingly, in our previous investigation we found A-80 non-immunoreactive tumours to be often highly differentiated and of DNA diploid type. In contrast, moderately and strongly A-80
immunostained carcinomas had often a lower grade of differentiation and exhibited frequently aneuploid DNA distribution patterns (Eriksson et al., 1992) . Against the background of these earlier findings, we conducted the present study on the interrelationship between the immunohistochemical A-80 expression, the nuclear DNA histogram type, and the clinical course in breast cancer patients. In univariate analysis, an interesting association between the degree of immunohistochemical MAb A-80 expression and the clinical course was found. The greatest difference in distant metastases-free survival was observed between MAb A-80 negative breast carcinomas and tumours with strong immunostaining patterns of more than 50% of their neoplastic cells (3 +). Invasive carcinomas with less intense MAb A-80 expression (1 +, 2 +) represented an intermediate group. Most of the distant metastases and relapses occurred in the group of patients with MAb A-80 immunoreactive tumours within the first 5 years after initial surgery. In contrast, in the group of patients that had MAb A-80 negative tumours distant metastases occurred significantly later. The frequency of events decreased after 5 years of survival in both the A-80 immunoreactive and in the nonimmunoreactive group. It should be stressed that the degree of the A-80 expression yielded significant prognostic information not only in node positive, but also in node negative breast cancer disease. In this context, it is noteworthy that the intensively discussed prognostic value of some oncogene products and other tumour associated proteins has mostly been found in node positive breast cancer patients (Hayes et al., 1991; Henry et al., 1990; Slamon et al., 1987) .
In multivariate analysis, after adjustment for nodal status, tumour size, and DNA histogram type, the prognostic effect of A-80 expression was reduced to borderline significance. One has to keep in mind, however, that the prognostic significance of any new tumour parameter has to be considered against the strong statistical effects of the established tumour characteristics with prognostic impact. Through mammographic screening programs an increasing number of breast cancers might be diagnosed in future. This might not only include an increasing number of in situ carcinomas, but also invasive carcinomas of small size without lymph node involvement. Though Jansson et al., 1988 The exact function of the mucin-type A-80 glycoprotein is still unknown. However, some recent reports added further information. Evidence has been obtained that the A-80 glyco-protein is present in foetal colonic epithelium and in reparative, hyperplastic and benign neoplastic colon epithelium, though at lower levels than in invasive colon carcinomas. Similar observations were made in breast tissue. We found strong A-80 immunoreactivity in normal apocrine sweat glands from the axilla (Eriksson et al., 1992) . Interestingly, aprocrine metaplasias frequently were also A-80 immunoreactive, which might indicate the close histogenetic relationship between these two types of glands (Eriksson et al., 1992) . Against this background, one might suggest that strong A-80 immunoreactivity in invasive breast carcinomas might indicate a relatively low grade of histogenetic differentiation. It is interesting to note that MAb A-80 expression seems to be associated with the genetic instability of a tumour. This is indicated by the observation that absence of A-80 immunoreactivity was frequently connected with tumours of DNA diploid type. In contrast, elevated levels of A-80 immunostaining were mostly observed in tumours of DNA aneuploid type.
In conclusion, the findings of the present study indicate that the degree of immunohistochemial expression of MAb A-80 is closely related to the distant metastases-free survival in breast cancer patients. Our pilot studies have shown that MAb A-80 immunostaining can be performed in cytospin preparations of fine-needle aspirates taken from breast cancer patients (Eriksson et al., 1992) . It might thus be suggested that these preoperatively taken samples might at an early stage be included in a multifactor risk assessment for the individual treatment of certain breast cancer patients.
